Welcome to our dedicated page for TILRAY BRANDS news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on TILRAY BRANDS stock.
TIlray Brands, Inc. (TLRY) generates frequent news as a global lifestyle and consumer packaged goods company active across cannabis, beverage, wellness, and entertainment categories. Company updates often highlight developments in its cannabis brands, medical cannabis operations, beverage portfolio, and strategic corporate actions, giving investors and followers insight into how Tilray is executing its multi-category strategy.
News coverage commonly includes financial results and segment performance across cannabis, beverage, wellness, and distribution, as reflected in Tilray’s quarterly earnings releases. These updates may discuss trends in international medical cannabis revenue, Canadian adult-use cannabis sales, and distribution activity through Tilray Pharma. Corporate announcements, such as the implementation of a one-for-ten reverse stock split and related shareholder decisions, are also reported through press releases and SEC filings.
Tilray’s brand and product news provides detail on new launches and category expansion. Recent communications feature Dry January and holiday guides showcasing hemp-derived THC beverages, zero-proof spirits, non-alcoholic beers, and craft beers, as well as cannabis-infused beverages under brands like Mollo and XMG. Other releases focus on innovations in cannabis vapes and concentrates under brands such as Good Supply and Redecan, and curated cannabis gift guides that reflect consumer trends in Canada.
Regulatory and medical developments are another important theme. Tilray Medical has issued statements on U.S. federal cannabis rescheduling and the creation of Tilray Medical USA, outlining a framework for U.S. medical cannabis expansion based on experience in regulated international markets. For readers tracking TLRY, this news stream offers context on how the company responds to policy changes, evolves its brand portfolio, and communicates with shareholders. Bookmark this page to access an organized feed of Tilray’s earnings releases, product announcements, regulatory updates, and other material company news.
Tilray Medical (Nasdaq: TLRY) on Jan 22, 2026 launched Tilray Medical Italia, the rebranded entity previously known as FL Group, to unify and scale its medical cannabis platform in Italy. The move includes a partnership with Molteni Farmaceutici and distribution through hospital and pharmacy channels under authorization from the Italian Ministry of Health. Products are EU‑GMP certified and available by prescription, spanning cannabis flowers (THC 25%, 18%, 9%/CBD 9%) and multiple THC:CBD oil formulations. The launch aligns with Tilray Medical’s pan‑European strategy and regulatory-focused growth approach.
Tilray Brands (Nasdaq: TLRY) reported a record Q2 fiscal 2026 with net revenue of $217.5M ($218M rounded), driven by a 36% increase in international cannabis and a 6% rise in Canadian adult‑use cannabis. Distribution (including Tilray Pharma) hit a quarterly high of $85.3M. Gross profit was $57.5M and adjusted EBITDA was $8.4M. The company improved its net loss to $(43.5)M and reported $291.6M in cash and marketable securities, moving to a net cash position of $27.4M. Tilray reaffirmed full‑year adjusted EBITDA guidance of $62M–$72M.
Tilray Brands (Nasdaq: TLRY) launched a Dry January product collection on Jan 6, 2026 that includes hemp-derived Delta-9 THC sparkling cocktails and seltzers, premium zero-proof spirits, and multiple non-alcoholic craft beers.
Key SKUs include Happy Flower sparkling THC cocktails, Fizzy Jane’s THC seltzers, Mock One zero-proof spirits, Runner’s High non-alc beer, Montauk Brewing non-alc IPA and Golden, and 10 Barrel NA Apocalypse IPA. Products are available online and at select retailers nationwide.
Tilray (Nasdaq: TLRY) launched Mollo and XMG cannabis beverages for Dry January, promoting alcohol-free options with consistent cannabinoid profiles and bold flavours.
New Mollo four-packs include Blackberry and Wild Berry Açaí (each can: 10 mg THC / 20 mg CBG); Mollo classics and Orchard Chill’r carry 10 mg THC / 10 mg CBG. XMG line includes flavored sodas, zero-sugar variants, and Atomic Sours, most cans featuring 10 mg THC (many also 10 mg CBG) and select SKUs with guarana.
The release cites the non-alcoholic beverage market up 24% YoY to $199M and notes products are available nationwide in Canada at select retailers, subject to provincial rules.
Tilray Brands (Nasdaq: TLRY) will release second fiscal quarter results for the period ended November 30, 2025 after market close on Thursday, January 8, 2026.
The company will host a live conference call and audio webcast at 4:30 PM Eastern Time that day; the webcast will be available on the Events & Presentations section of Tilray’s investor relations website.
Investor Q&A will be open via Robinhood and Say Technologies beginning today through January 7, 2026, and questions can be submitted or upvoted on those platforms.
Tilray (Nasdaq: TLRY) announced formation of Tilray Medical USA on Dec 18, 2025 to accelerate its planned U.S. medical cannabis expansion after federal cannabis rescheduling. The company highlighted its global medical footprint: 200+ registered medical cannabis products, > 500,000 registered patients served, and participation in > 15 clinical studies. Tilray said it will leverage compliance systems, scientific expertise, and physician partnerships to introduce medical-grade products and support research and clinical trials under evolving U.S. regulation.
Tilray Brands (Nasdaq: TLRY) announced Redecan’s launch of Amped Live Resin Liquid Diamond 1g 510 cartridges, the brand’s first live resin–liquid diamond vape line, debuting Space Age CK and Blueberry DNTS on December 11, 2025.
Amped pairs 80% Legit Live Resin with 20% Liquid Diamonds, uses an in‑house grown-to-pack process with no fillers or cutting agents, and features the TrueDraw Ceramic core and wide‑body hardware to improve airflow and reduce clogs. The product is available now in Ontario and Alberta, with national distribution scheduled for early 2026. The release cites a 6.3% six‑month category growth for Live Resin Vapes and notes winter (Dec–Feb) vape penetration peaks aligning with the launch.
Tilray (Nasdaq: TLRY) released the Ultimate 2025 Holiday Drink Gift Guide on December 4, 2025, showcasing a curated selection of craft beers, premium spirits, ready-to-drink cocktails and hemp-derived THC beverages for North American holiday gifting.
Highlights include Breckenridge whiskey releases, Mountain Shot, Fizzy Jane’s 10 mg Lemon Lime, Happy Flower 5 mg Delta-9 THC cans, 10Barrel and Cruisies RTD lines, non-alcoholic options, regionally themed beer recommendations, and seasonal taproom events across Tilray brewery locations.
Tilray Brands (Nasdaq: TLRY) released its 2025 Cannabis Holiday Gift Guide on December 4, 2025, highlighting Canadians' top cannabis picks for gifting and entertaining.
The guide showcases leading products across price points and categories—pre-rolls, craft flower, infused beverages, edibles, and premium chocolates—and names specific SKUs such as Double Dutchies, Jean Guy, XMG Atomic Sour 5-packs, Mollo seltzers and more. It cites Statistics Canada retail cannabis sales of nearly $500 million in December 2024 as context for a busy holiday retail period.
Tilray Brands (Nasdaq: TLRY) will implement a 1-for-10 reverse stock split, effective at 4:01 pm ET on December 1, 2025, with shares trading on a split-adjusted basis on December 2, 2025 under the same ticker TLRY and new CUSIP 88688T209.
Every ten issued and outstanding shares will be combined into one share, reducing outstanding common stock from approximately 1.16 billion to 116 million. Fractional shares will be paid in cash. The company said the split aims to align share count with peers, attract institutional investors, and reduce annual meeting costs by up to $1 million on a run-rate basis. Stockholders of record will receive transaction statements; brokerage positions will be adjusted automatically.